Company Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma.
Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial.
Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 497 |
| CEO | Dr. Bahija Jallal Ph.D. |
Contact Details
Address: 90 Park Drive, Milton Park, Abingdon Oxfordshire, X0 OX14 4RY United Kingdom | |
| Phone | 01235 5430281 |
| Website | immunocore.com |
Stock Details
| Ticker Symbol | IMCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $26.00 |
| CIK Code | 0001671927 |
| CUSIP Number | 45258D105 |
| ISIN Number | US45258D1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bahija Jallal Ph.D. | Chief Executive Officer and Director |
| Brian R. Di Donato M.B.A. | Chief Financial Officer and Head of Strategy |
| John Trainer M.B.A. | SVice President and Chief Operating Officer |
| John Goll III | SVice President, Finance and Chief Accounting Officer |
| Annelise Vuidepot Ph.D. | Chief Technology Officer and Head of Pipeline and Platform Research |
| Sean D. Buckley | Vice President and Chief Information Officer |
| Clayton Robertson | Head of Investor Relations |
| Lily Margaret Hepworth | General Counsel and Company Secretary |
| Elizabeth Varki Jobes Esq., J.D. | Chief Compliance Officer |
| Sébastien Desprez | Head of Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 424B7 | Filing |
| Apr 2, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | 144 | Filing |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |